Dirk M Nettelbeck
Overview
Explore the profile of Dirk M Nettelbeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1438
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kontermann R, Ungerechts G, Nettelbeck D
MAbs
. 2021 Nov;
13(1):1982447.
PMID: 34747345
Cancer therapeutics approved for clinical application include oncolytic viruses and antibodies, which evolved by nature, but were improved by molecular engineering. Both facilitate outstanding tumor selectivity and pleiotropic activities, but...
2.
Buning H, Fehse B, Ivics Z, Kochanek S, Koehl U, Kupatt C, et al.
Hum Gene Ther
. 2021 Oct;
32(19-20):987-996.
PMID: 34662229
Gene therapies have been successfully applied to treat severe inherited and acquired disorders. Although research and development are sufficiently well funded in Germany and while the output of scientific publications...
3.
Nettelbeck D, Leber M, Altomonte J, Angelova A, Beil J, Berchtold S, et al.
Viruses
. 2021 Aug;
13(8).
PMID: 34452286
Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction...
4.
Joos S, Nettelbeck D, Reil-Held A, Engelmann K, Moosmann A, Eggert A, et al.
Mol Oncol
. 2018 Dec;
13(3):535-542.
PMID: 30561127
The German Cancer Consortium ('Deutsches Konsortium für Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and...
5.
Krackhardt A, Anliker B, Hildebrandt M, Bachmann M, Eichmuller S, Nettelbeck D, et al.
Cancer Immunol Immunother
. 2018 Jan;
67(4):513-523.
PMID: 29380009
Adoptive transfer of T cells genetically modified by TCRs or CARs represents a highly attractive novel therapeutic strategy to treat malignant diseases. Various approaches for the development of such gene...
6.
Ungerechts G, Engeland C, Buchholz C, Eberle J, Fechner H, Geletneky K, et al.
Hum Gene Ther
. 2017 Sep;
28(10):800-819.
PMID: 28870120
Virotherapy is a unique modality for the treatment of cancer with oncolytic viruses (OVs) that selectively infect and lyse tumor cells, spread within tumors, and activate anti-tumor immunity. Various viruses...
7.
Havunen R, Siurala M, Sorsa S, Gronberg-Vaha-Koskela S, Behr M, Tahtinen S, et al.
Mol Ther Oncolytics
. 2017 Mar;
4:77-86.
PMID: 28345026
Adoptive cell therapy holds much promise in the treatment of cancer but results in solid tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) therapy of melanoma, but...
8.
Knippertz I, Deinzer A, Dorrie J, Schaft N, Nettelbeck D, Steinkasserer A
J Immunol Res
. 2016 Jul;
2016:6078473.
PMID: 27446966
To specifically target dendritic cells (DCs) to simultaneously express different therapeutic transgenes for inducing immune responses against tumors, we used a combined promoter system of adenoviral vectors. We selected a...
9.
Ungerechts G, Bossow S, Leuchs B, Holm P, Rommelaere J, Coffey M, et al.
Mol Ther Methods Clin Dev
. 2016 Apr;
3:16018.
PMID: 27088104
Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse viruses,...
10.
Kaczorowski A, Hammer K, Liu L, Villhauer S, Nwaeburu C, Fan P, et al.
Oncotarget
. 2016 Jan;
7(8):9046-59.
PMID: 26824985
Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies and has poor therapeutic options. We evaluated improved oncolytic adenoviruses (OAds), in which the adenoviral gene E1B19K was deleted...